LONG
BEACH, Calif., May 16, 2024
/PRNewswire/ -- A new analysis of a study comparing two commonly
used medications, chlorthalidone (CTD) and hydrochlorothiazide
(HCTZ), is set to be presented as a late-breaking presentation at
the annual 2024 National Kidney Foundation Spring Clinical
Meetings.
New study comparing two commonly used
medications set to be shared as a late-breaking presentation at
NKF's Conference.
The study, titled "Treatment with Chlorthalidone vs
Hydrochlorothiazide and Renal Outcomes: The Diuretic Comparison
Project (DCP)," conducted by a team of distinguished researchers
from various institutions and led by Areef
Ishani, MD MS, Minneapolis VA Health Care System Primary
Care and Specialty Care Integrated Care Community (ICC) Director
and Professor of Medicine, University of Minnesota provides
crucial insights into the impact of these medications on renal
health in hypertensive patients.
Hypertension, or high blood pressure, is a significant risk
factor for the development and progression of chronic kidney
disease (CKD). Previous research had hinted at potential
differences in kidney outcomes between chlorthalidone and
hydrochlorothiazide. This new study followed more than 12,000
participants for an average of 3.9 years.
The study found no significant disparity in renal outcomes
between patients treated with chlorthalidone and those treated
with hydrochlorothiazide. Specifically, there was no marked
difference observed in the primary composite renal outcome,
including doubling of serum creatinine, a significant drop in
estimated glomerular filtration rate (eGFR), or kidney failure
requiring treatment (KFRT), between the two treatment groups.
Furthermore, the study revealed that the total slope
of eGFR change and the incidence of chronic kidney disease
(CKD) were comparable between patients receiving chlorthalidone and
hydrochlorothiazide, suggesting similar efficacy in preserving
kidney function. The findings offer reassurance that both
chlorthalidone and hydrochlorothiazide may be equally effective
choices for managing hypertension without compromising renal
health.
About NKF Spring Clinical Meetings
For the past 32
years, nephrology healthcare professionals from across the country
have come to NKF's Spring Clinical Meetings to learn
about the newest developments related to all aspects of nephrology
practice; network with colleagues; and present their research
findings. The NKF Spring Clinical Meetings is designed for
meaningful change in the multidisciplinary healthcare teams'
skills, performance, and patient health outcomes. It is the
only conference of its kind that focuses on translating science
into practice for the entire healthcare team.
About Kidney Disease
In the United States, more than 37
million adults are estimated to have kidney disease, also known as
chronic kidney disease (CKD)—and approximately 90 percent don't
know they have it. About 1 in 3 adults in the U.S. are at risk for
kidney disease. Risk factors for kidney disease
include: diabetes, high blood pressure, heart
disease, obesity, and family history. People of Black or
African American, Hispanic or Latino, American Indian or Alaska
Native, Asian American, or Native Hawaiian or Other Pacific
Islander descent are at increased risk for developing the disease.
Black or African American people are about four times as likely as
White people to have kidney failure. Hispanics experience
kidney failure at about double the rate of White people.
About NKF Professional Memberships
Healthcare professionals can join NKF to receive access
to tools and resources for both patients and professionals,
discounts on professional education, and access to a network of
thousands of individuals who treat patients with kidney
disease.
About the National Kidney Foundation
The National Kidney Foundation is revolutionizing the fight to save
lives by eliminating preventable kidney disease, accelerating
innovation for the dignity of the patient experience, and
dismantling structural inequities in kidney care, dialysis, and
transplantation.
NKF Website
Instagram
Facebook
X
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-analysis-on-hypertension-treatment-to-be-presented-as-late-breaking-research-at-national-kidney-foundation-spring-clinical-meetings-302148182.html
SOURCE The National Kidney Foundation